



Cognitive Function in Hospitalized Patients with Multiple Sclerosis: A Case-Control Study

Ali Reza Shafiee-Kandjani^{1,2}, Shahrokh Amiri^{2,3,*}, Zahra Mousavi³, Mazyar Hashemilar⁴, Salman Safikhanlou³, Salman Abdi¹ and Majid Khalili⁵

¹Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

²Department of Psychiatry, Razi Mental Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

³Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Department of Neurology, Tabriz University of Medical Sciences, Tabriz, Iran

⁵Department of Basic Sciences, Maragheh University of Medical Sciences, Maragheh, Iran

*Corresponding author: Department of Psychiatry, Razi Mental Hospital, El Goli Blvd., P.O. Box: 5456, Tabriz, Iran. Tel/Fax: +98-4133803351, Email: sh_amiri1348@yahoo.com

Received 2019 January 20; Revised 2019 March 03; Accepted 2019 May 11.

Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory disease characterized by central nervous system lesions that can lead to severe cognitive and physical disability, as well as neurological deficits such as attention and memory decline. The complications may bring about many difficulties for patients in educational and occupational functioning and low quality of life.

Objectives: Considering the remarkable prevalence of cognitive deficits and its important effects on the occupational and social functioning of MS patients, this study was conducted to investigate cognitive deficits in these patients compared to a control group.

Methods: This case-control study was carried out on 34 MS patients selected from among patients admitted to Imam Reza Hospital and Razi Psychiatric Hospital in Tabriz, Iran. Moreover, a control group of 34 age and gender-matched patients admitted to internal wards was formed. The Persian version of the paper and pencil cognitive assessment package (PCAP) was used to assess cognitive functions. Data analysis was performed using SPSS version 22 software through descriptive statistics (mean and standard deviation) and inferential statistics (Student *t*-test and Pearson's correlation test). A *P* value of < 0.05 was considered statistically significant.

Results: The results of *t*-test showed that MS patients had lower PCAP mean scores than the control group in cognitive functions (executive function, attention, focus and work memory) (*P* < 0.05).

Conclusions: The findings of this preliminary study confirmed that MS patients suffered from cognitive impairments. The assessment of cognitive functions must be done in MS patients. Cognitive enhancement therapy would be helpful for afflicted patients.

Keywords: Attention, Cognitive Functions, Executive Function, Multiple Sclerosis, Working Memory

1. Background

Multiple sclerosis (MS) is the most common cause of progressive neurodegenerative diseases in young adults with a profound effect on the social, economic, psychological, and sexual aspects of affected people (1). The prevalence of MS in the USA is up to 149.2 per 100000 population (2). A study showed that the MS prevalence rate is 31 to 55 per 100000 population in the Persian Gulf countries. The reported prevalence for Turkey and Jordan are 51 and 20 per 100000 population, respectively. In Iran, the highest and lowest prevalence rates belong to Isfahan (93.06 per 100000) and Golestan (18.0 per 100000) provinces, respectively (3). The MS incidence increased from 1991 to 2004 in Tehran, Iran. The annual percent change (APC) was 12.8% in women and 12.5% in men in the same period (4). The prevalence in women is 3.13 times the prevalence in men (5).

Cognitive deficits are seen in 40% to 65% of patients (6,

7). MS affects different cognitive domains (8) and cognitive deficits can be seen in the early stages of MS symptoms development (9). Cognitive function is an intellectual process that enables individuals to be aware of, perceive, and comprehend the ideas. Making a decision and manifesting behavior are considered as its targets. Therefore, it is important to consider the cognitive functioning of MS patients in clinical evaluations (8). In this regard, previous reports showed a delay in reaction time and deficiency in the information processing speed of the mind and consequently impaired memory in these patients (10-12). It also has been reported that the most frequently impaired domains were attention (50.4%), information processing speed (26.5%), memory (12.4%), visuospatial function (8.8%), and language (1.8%). In patients displaying deficits in two cognitive domains, the most frequent combinations were attention and information processing speed (33.3%), attention and memory (19.3%), information processing speed

and memory (19.3%), attention and visuospatial function (8.8%), and attention and language (5.3%). At least three cognitive domains were affected in 23.2% of the patients (7). Concerning previous reports, cognitive impairment is a common feature of MS that affects more than half of the MS patients. It has a sophisticated neuroanatomical and pathophysiologic background and disturbs such vital cognitive domains as the speed of information processing, memory, attention, executive functions, and visuospatial functions (13).

Previous studies have reported that cognitive impairment is common in MS patients (6, 7). Moreover, patients with primary progressive MS have had more severe cognitive impairment than patients with relapsing-remitting MS, indicating the role of disease course in cognitive impairment development (14). Some other studies indicated that processing speed is much more impaired than working memory in MS (15). There are several paradoxical points in assessing cognitive functions in MS; however, new perspectives in neuro-anatomical or neurophysiological research demonstrate EEG/MEG features as a promising procedure that may reduce the paradox and yield a better understanding in this field (16).

2. Objectives

Considering the geographic diversity and different prevalence rates of MS all over the world (2-4, 17, 18), the impacts of cognitive decline on the quality of life of MS patients, and the contradictory results of studies in this field, the aim of the current study was to compare cognitive functions in three areas of working memory, attention, and executive function in hospitalized MS patients and other patients hospitalized in internal wards.

3. Methods

3.1. Participants

This cross-sectional study was performed at Imam Reza Educational Center and Razi Educational Hospital affiliated to Tabriz University of Medical Sciences, Tabriz, Iran, in 2018. The sample was selected using a nonrandom convenience sampling method from among patients admitted to the neurology departments of the two centers. Furthermore, 34 age and gender-matched people were recruited from internal wards as a control group. G*Power software was used to calculate the sample size regarding the mean scores in the symbol digit modalities test (SDMT) of PCAP. The participants were selected from among 20 to 35-year-old patients in accordance with a previous study (19).

All ethical codes including obtaining informed consent, confidentiality and non-disclosure of patient information, and continuation of routine treatment strategy

were taken into consideration. The study was performed under the regional ethical code IR.TBZMED.REC.1395.1008.

3.2. Inclusion and Exclusion Criteria

Written consent to participate in the study, a diagnosis of MS by a neurologist, an age of 20 - 35-years-old, and ability to read and write were considered as the inclusion criteria. Psychiatric illnesses such as attention deficit hyperactivity disorder (ADHD), schizophrenia, dementia, acute phase of mood disorder, substance use, and mental retardation that would affect cognitive functions were considered as the exclusion criteria. The diagnosis of psychiatric comorbidities was established during psychiatric clinical interviews.

3.3. Tools

The Persian version of paper and pencil cognitive assessment package (PCAP) was used in the study. It is a collection of the most common and applicable cognitive assessment tests covering various areas of memory and learning, working memory, attention, and executive functions. This package includes symbol digit modality test (SDMT), letter-number sequencing task (LNST), trail making task, verbal fluency task, and stroop task. A study conducted by Rezapour et al. (20) confirmed the validity and reliability of the PCAP in Iranian populations.

3.4. Statistical Analysis

The sample size was assessed by the G*Power software using the SDMT of PCAP applied on 31 individuals in each group of MS patients and non-MS controls that were increased to 34 subjects after considering a 10% dropout rate. Data analysis was performed by SPSS version 22 software (SPSS, Chicago, IL, USA) using descriptive statistics (mean and standard deviation.) and inferential statistics (Student *t*-test and Pearson's correlation test). A *P* value of < 0.05 was considered statistically significant.

4. Results

In this study, 68 individuals (34 MS patients and 34 controls) were evaluated. The mean age was 32.44 ± 3.43 in the MS group and 31.17 ± 3.63 in the control group. There was no significant difference between the two groups in age ($P > 0.05$, $t = 47.1$).

According to Table 1, the majority of the participants in both groups were women and according to the Fisher's exact test, there was no statistically significant difference between the two groups regarding the frequency distribution of gender and education.

According to Table 2, the mean score of the forward digit span task (FDST) test was 5.85 in the patient group and 7.85 in the control group; the mean score of the LNST test

Table 1. Frequency Distribution of MS Patients and Controls Based on Gender and Education Level

Variables	Control Group ^a	MS Group ^a	χ^2	df	P Value
Sex			0.09	1	1
Female	28 (82.4)	27 (79.4)			
Male	6 (17.6)	7 (20.6)			
Education			4.57	2	0.10
High school	12 (35.3)	20 (58.8)			
Diploma	16 (47.1)	12 (35.3)			
Academic degree	6 (17.6)	2 (5.9)			

Abbreviation: MS, multiple sclerosis.
^aValues are expressed as No. (%).

was 4.23 in the patient group and 7.82 in the control group; the mean score of the SDMT test was 30.33 in the patient group and 49.29 in the control group; the mean score of the letter digit modality test (LDMT) was 35.30 in the patient group and 55.17 in the control group; the mean score of trail making task A test was 49.39 in the patient group and 24.26 in the control group; and the mean score of the stroop task color time test was 217.66 in the case group and 118.29 in the control group.

The Independent *t*-test (Table 2) showed significant differences between the two groups of participants in all scales mentioned above. Considering the results, the mean scores of cognitive indices were lower in MS patients than in controls (Figure 1).




Figure 1. Comparison of cognitive functions in MS patients and controls

5. Discussion

This study was conducted to compare the cognitive function of MS patients and a control group. Several studies have examined the presence of cognitive impairment in MS but a few studies have assessed a variety of cognitive impairments that may affect the occupational and social functions of individuals. Identifying these cognitive impairments provides us with the possibility of adopting more effective therapeutic strategies. Therefore, in the present study, three areas including attention, working memory, and executive functions were examined.

In line with other studies (11, 21-23), the results of the FDST and BDST demonstrated that the working memory of MS patients was significantly poorer than that of the control group ($P = 0.001$ for both). The findings indicated that working memory decline is the most common cognitive impairment in MS as seen in more than half of the patients. Among other reasons for dysfunction in the memory of these patients are fatigue and depression that should be taken seriously into consideration (24).

Language capacity and immediate, implicit, and recognition memory are not impaired generally. One of the contradictory results associated with recognition memory was found in the study by Rogers and Panegyres (24). Some authors indicated a non-significant difference in semantic and recognition memory function of MS patients (25). However, this contradiction can have different reasons. The controversy may stem from the different neuropsychological tests used, as well as sampling in different phases of MS, as sampling in acute and recovery phases can lead to diversity in results. In the present study, data were gathered from hospitalized patients who were in the acute phase.

Verbal fluency task was also evaluated in this study. Both words and classification features of this test were significantly different in MS patients compared to controls ($P = 0.001$). The results of several studies showed that verbal fluency performance was more impaired in MS patients than in control subjects (26-28).

The attention scores of MS patients were significantly lower than the scores of the control group (based on SMDT

Table 2. Comparison of Cognitive Function-Related Tests in MS Patients and Controls

Tests	Mean \pm SD	P Value
Forward digit span task		0.001
Control	7.85 \pm 1.96	
MS	5.85 \pm 1.48	
Backward digit span task		0.001
Control	5.97 \pm 1.24	
MS	3.47 \pm 0.89	
Letter-number sequencing task		0.001
Control	7.82 \pm 2.80	
MS	4.23 \pm 1.20	
Symbol digit modality test		0.001
Control	49.29 \pm 8.06	
MS	30.33 \pm 10.68	
Letter digit modality test		0.001
Control	5.17 \pm 9.24	
MS	35.30 \pm 12.78	
Verbal fluency task (words)		0.001
Control	36.76 \pm 7.66	
MS	21.75 \pm 8.08	
Verbal fluency task (classification)		0.001
Control	46.47 \pm 10.21	
MS	37.03 \pm 8.88	
Trail making task (A)		0.001
Control	24.26 \pm 6.14	
MS	49.39 \pm 26.57	
Trail making task (B)		0.001
Control	45.76 \pm 10.41	
MS	67.67 \pm 10.77	
Stroop task color time		0.02
Control	118.29 \pm 32.06	
MS	217.66 \pm 253.99	
Stroop task color error		0.04
Control	0.26 \pm 0.66	
MS	1.24 \pm 2.64	
Stroop task word time		0.03
Control	115.91 \pm 27.83	
MS	258.27 \pm 389.11	
Stroop task word error		0.04
Control	0.08 \pm 0.37	
MS	1.33 \pm 3.61	
Stroop task word color time		0.001
Control	181.26 \pm 41.05	
MS	336.93 \pm 224.45	
Stroop task word color error		0.003
Control	1.70 \pm 1.52	
MS	4.75 \pm 5.46	

Abbreviations: MS, multiple sclerosis; SD, standard deviation.

and LNST; $P = 0.001$). Therefore, attention is more impaired in MS patients than in controls. These findings are consistent with previous studies (29, 30). It was also shown that the symptoms of adult ADHD are more common in MS patients than in control counterparts (31).

Cognitive processing speed and executive functioning were also impaired in multiple sclerosis based on trail making tasks A and B ($P = 0.001$ for both). Stroop tests showed a significant deficit in executive functioning, too (stroop task word color time and error; $P = 0.001$). The current study confirms the impairment of executive function in MS patients in the acute phase probably because of axonal degeneration, inflammatory demyelination of the central nervous system, and pain feeling. Pain may have negative impacts on attention, too. Therefore, we need to improve attention and executive functioning of MS patients while establishing therapeutic interventions and cognitive training (29, 32, 33).

5.1. Limitations and Further Studies

This study was conducted among MS patients in the acute phase hospitalized in neurology wards. Therefore, the illness severity may be a reason for more acute impairment of executive function. It is suggested that the correlation between illness severity and executive function be examined in future studies. In addition, examining the efficacy of pharmacotherapy in the improvement of executive functions could be a goal for further studies.

Acknowledgments

Hereby, many thanks go to all patients participating in this study and their families for their cooperation.

Footnotes

Conflict of Interests: The authors have no conflict of interests.

Ethical Approval: It was approved by the Regional Committee of Ethics under code number: IR.TBZMED.REC.1395.1008.

Funding/Support: Tabriz University of Medical Sciences funded the study. This research paper was extracted from psychiatry specialty dissertation of Dr Zahra Mousavi with the Reg. No. 58096 affiliated to Tabriz University of Medical Sciences.

References

- McCabe MP, Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap III LC, et al. *Williams Obstetrics*. 22nd ed. New York: McGraw-Hill; 2005.
- Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. *Neurology*. 2016;**86**(11):1014–21. doi: [10.1212/WNL.0000000000002469](https://doi.org/10.1212/WNL.0000000000002469). [PubMed: 26888980]. [PubMed Central: [PMC4799713](https://pubmed.ncbi.nlm.nih.gov/PMC4799713/)].
- Tolou-Ghamari Z. A review of geoepidemiological differences of multiple sclerosis in Iran and other Middle East countries. *Arch Neurosci*. 2014;**2**(3). doi: [10.5812/archneurosci.22028](https://doi.org/10.5812/archneurosci.22028).

4. Eskandarieh S, Heydarpour P, Elhami SR, Sahraian MA. Prevalence and incidence of multiple sclerosis in Tehran, Iran. *Iran J Public Health*. 2017;**46**(5):699-704. [PubMed: [28560202](#)]. [PubMed Central: [PMC5442284](#)].
5. Harbo HF, Gold R, Tintore M. Sex and gender issues in multiple sclerosis. *Ther Adv Neurol Disord*. 2013;**6**(4):237-48. doi: [10.1177/1756285613488434](#). [PubMed: [23858327](#)]. [PubMed Central: [PMC3707353](#)].
6. Jongen PJ, Ter Horst AT, Brands AM. Cognitive impairment in multiple sclerosis. *Minerva Med*. 2012;**103**(2):73-96. [PubMed: [22513513](#)].
7. Matias-Guiu JA, Cortes-Martinez A, Valles-Salgado M, Oreja-Guevara C, Pytel V, Montero P, et al. Functional components of cognitive impairment in multiple sclerosis: A cross-sectional investigation. *Front Neurol*. 2017;**8**:643. doi: [10.3389/fneur.2017.00643](#). [PubMed: [29234305](#)]. [PubMed Central: [PMC5712315](#)].
8. Nabavi SM, Sangelaji B. Cognitive dysfunction in multiple sclerosis: Usually forgotten in the clinical assessment of MS patients. *J Res Med Sci*. 2015;**20**(5):533-4. [PubMed: [26487885](#)]. [PubMed Central: [PMC4590211](#)].
9. Schulz D, Kopp B, Kunkel A, Faiss JH. Cognition in the early stage of multiple sclerosis. *J Neurol*. 2006;**253**(8):1002-10. doi: [10.1007/s00415-006-0145-8](#). [PubMed: [16609812](#)].
10. Reicker LI, Tombaugh TN, Walker L, Freedman MS. Reaction time: An alternative method for assessing the effects of multiple sclerosis on information processing speed. *Arch Clin Neuropsychol*. 2007;**22**(5):655-64. doi: [10.1016/j.acn.2007.04.008](#). [PubMed: [17532182](#)].
11. Rao SM. Cognitive function in patients with multiple sclerosis: Impairment and treatment. *Int J MS Care*. 2004;**6**(1):9-22. doi: [10.7224/1537-2073-6.1.9](#).
12. Rouleau I, Dagenais E, Tremblay A, Demers M, Roger E, Jobin C, et al. Prospective memory impairment in multiple sclerosis: A review. *Clin Neuropsychol*. 2018;**32**(5):922-36. doi: [10.1080/13854046.2017.1361473](#). [PubMed: [28774220](#)].
13. Grzegorski T, Losy J. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research. *Rev Neurol*. 2017;**28**(8):845-60. doi: [10.1515/revneuro-2017-0011](#). [PubMed: [28787275](#)].
14. Johnen A, Landmeyer NC, Burkner PC, Wiendl H, Meuth SG, Holling H. Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2017;**83**:568-78. doi: [10.1016/j.neubiorev.2017.09.005](#). [PubMed: [28890199](#)].
15. Genova HM, Lengenfelder J, Chiaravalloti ND, Moore NB, DeLuca J. Processing speed versus working memory: Contributions to an information-processing task in multiple sclerosis. *Appl Neuropsychol Adult*. 2012;**19**(2):132-40. doi: [10.1080/09084282.2011.643951](#). [PubMed: [23373581](#)]. [PubMed Central: [PMC3564503](#)].
16. Van Schependom J, Nagels G. Targeting cognitive impairment in multiple sclerosis-the road toward an imaging-based biomarker. *Front Neurosci*. 2017;**11**:380. doi: [10.3389/fnins.2017.00380](#). [PubMed: [28713238](#)]. [PubMed Central: [PMC5491975](#)].
17. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. *Rev Neurol (Paris)*. 2016;**172**(1):3-13. doi: [10.1016/j.neurol.2015.10.006](#). [PubMed: [26718593](#)].
18. Ramagopalan SV, Hoang U, Seagroatt V, Handel A, Ebers GC, Giovannoni G, et al. Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: A descriptive study. *J Neurol Neurosurg Psychiatry*. 2011;**82**(6):682-7. doi: [10.1136/jnnp.2010.232108](#). [PubMed: [21212107](#)]. [PubMed Central: [PMC3090127](#)].
19. Baysal Kirac L, Ekmekci O, Yuceyar N, Sagduyu Kocaman A. Assessment of early cognitive impairment in patients with clinically isolated syndromes and multiple sclerosis. *Behav Neurol*. 2014;**2014**:637694. doi: [10.1155/2014/637694](#). [PubMed: [25944978](#)]. [PubMed Central: [PMC4402565](#)].
20. Rezapour T, Ekhtiyari H, Soltaninejad Z. [procedure and scoring of Persian paper and pencil cognitive assessment package (PCAP)]. Tehran: Mehrsa; 2013. Persian.
21. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. *Lancet Neurol*. 2008;**7**(12):1139-51. doi: [10.1016/S1474-4422\(08\)70259-X](#). [PubMed: [19007738](#)].
22. Fuso SF, Callegaro D, Pompeia S, Bueno OF. Working memory impairment in multiple sclerosis relapsing-remitting patients with episodic memory deficits. *Arq Neuropsiquiatr*. 2010;**68**(2):205-11. [PubMed: [20464286](#)].
23. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R, et al. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. *Mult Scler*. 2017;**23**(5):721-33. doi: [10.1177/1352458517690821](#). [PubMed: [28206827](#)]. [PubMed Central: [PMC5405816](#)].
24. Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: Evidence-based analysis and recommendations. *J Clin Neurosci*. 2007;**14**(10):919-27. doi: [10.1016/j.jocn.2007.02.006](#). [PubMed: [17659875](#)].
25. Rao SM, Grafman J, DiGiulio D, Mittenberg W, Bernardin L, Leo G, et al. Memory dysfunction in multiple sclerosis: Its relation to working memory, semantic encoding, and implicit learning. *Neuropsychology*. 1993;**7**(3):364-74. doi: [10.1037/0894-4105.7.3.364](#).
26. Vlaar AM, Wade DT. Verbal fluency assessment of patients with multiple sclerosis: Test-retest and inter-observer reliability. *Clin Rehabil*. 2007;**17**(7):756-64. doi: [10.1191/0269215503cr6740a](#). [PubMed: [14606742](#)].
27. Henry JD, Beatty WW. Verbal fluency deficits in multiple sclerosis. *Neuropsychologia*. 2006;**44**(7):1166-74. doi: [10.1016/j.neuropsychologia.2005.10.006](#). [PubMed: [16293271](#)].
28. Sandry J, Genova HM, Dobryakova E, DeLuca J, Wylie G. Subjective cognitive fatigue in multiple sclerosis depends on task length. *Front Neurol*. 2014;**5**:214. doi: [10.3389/fneur.2014.00214](#). [PubMed: [25386159](#)]. [PubMed Central: [PMC4209827](#)].
29. Macniven JA, Davis C, Ho MY, Bradshaw CM, Szabadi E, Constantinescu CS. Stroop performance in multiple sclerosis: Information processing, selective attention, or executive functioning? *J Int Neuropsychol Soc*. 2008;**14**(5):805-14. doi: [10.1017/S1355617708080946](#). [PubMed: [18764975](#)].
30. Denney DR, Lynch SG. The impact of multiple sclerosis on patients' performance on the Stroop Test: Processing speed versus interference. *J Int Neuropsychol Soc*. 2009;**15**(3):451-8. doi: [10.1017/S1355617709090730](#). [PubMed: [19402931](#)].
31. Alpua M, Turkel Y, Hn G, Oguzturk O, Dag E, Yoldas TK. Attention deficit/hyperactivity disorder in adults with multiple sclerosis. *Int J Ment Health Psychiatr*. 2017;**3**(3). doi: [10.4172/2471-4372.1000147](#).
32. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: Consequences for understanding the progressive phase of the disease. *J Neurol Sci*. 2003;**206**(2):165-71. [PubMed: [12559505](#)].
33. Hosseinzadegan F, Radfar M, Shafiee-Kandjani AR, Sheikh N. Efficacy of self-hypnosis in pain management in female patients with multiple sclerosis. *Int J Clin Exp Hypn*. 2017;**65**(1):86-97. doi: [10.1080/00207144.2017.1246878](#). [PubMed: [27935465](#)].